Post

New research · Ophthalmology
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 11h
Cohort studyJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2026

Optic Atrophy in Wolfram Syndrome Type 1: A Retrospective Analysis of Visual Outcomes and Biomarker Correlates.

Bradley J McNeely, Abby F Tang, Fumihiko Urano … Yunshuo Tang
Read paper
OphthalmologyCohort study

Vision loss tracks with thinner retinal ganglion cell complex in Wolfram syndrome type 1.

Optic Atrophy in Wolfram Syndrome Type 1: A Retrospective Analysis of Visual Outcomes and Biomarker Correlates.

Bradley J McNeely … Yunshuo Tang
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2026
Background

Wolfram syndrome type 1 (WS1) is a rare autosomal recessive disorder classically associated with diabetes mellitus (diabetes mellitus) and optic atrophy (optic atrophy).

Purpose

We aimed to characterize optic atrophy in WS1 and evaluate optical coherence tomography (optical coherence tomography) and genetic biomarkers as tools for disease monitoring and prognostication.

Methods

We conducted a retrospective chart review of genetically confirmed patients with WS1 seen at Washington University or Indiana University neuro-ophthalmology clinics between July 2017 and 2024.

n = 31 patients
R2 = 0.29
Results
R2 = 0.29
worse vision often paired with thinner nerve cell layer, but weakly
n = 31 patients
More results

Thirty-six patients (22 women, 14 men; median age 20 years) were identified.

Median mutation severity score was 3.5.

Vision loss occurred in 31 patients; in 3 patients it was the only major symptom, in 5 patients it preceded diabetes mellitus, and in 6 patients it occurred without diabetes mellitus.

More results

Mean and median BCVA were 20/125 and 20/80, respectively.

“
Conclusion · 1 of 2

Optic atrophy was the most common and sometimes earliest WS1 manifestation. Correlations between BCVA, optical coherence tomography metrics, and mutation severity score support their potential value as biomarkers and prognostic tools.

Conclusion · 2 of 2

Findings also support considering genetic screening for WFS1 mutations in patients presenting with otherwise unexplained optic atrophy.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving